Should I buy or sell Kronos Bio stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KRON shares. View KRON analyst ratings or view top-rated stocks .

What is Kronos Bio's stock price target for 2024?

2 brokerages have issued 12 month target prices for Kronos Bio's stock. Their KRON share price targets range from $2.50 to $6.00. On average, they expect the company's share price to reach $4.25 in the next twelve months. This suggests a possible upside of 312.6% from the stock's current price. View analysts price targets for KRON or view top-rated stocks among Wall Street analysts .

How have KRON shares performed in 2024?

Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON stock has decreased by 17.6% and is now trading at $1.03. View the best growth stocks for 2024 here .

When is Kronos Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our KRON earnings forecast .

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) issued its earnings results on Thursday, March, 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $2.29 million for the quarter, compared to analysts' expectations of $1.50 million. Kronos Bio had a negative trailing twelve-month return on equity of 58.79% and a negative net margin of 1,791.87%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KRON

Kronos Bio (KRON) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KRON Stock Alerts

$1.03

-0.01 (-0.96%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.00
▼
$1.07
50-Day Range: $1.02
▼
$1.38
52-Week Range: $0.73
▼
$2.29

Volume: 209,645 shs
Average Volume: 245,938 shs
Market Capitalization: $61.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.25

Get Kronos Bio alerts:

Kronos Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 312.6% Upside
$4.25 Price Target
Short Interest: Healthy
1.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$7,736 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.74) to ($1.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

Medical Sector

319th out of 918 stocks

Pharmaceutical Preparations Industry

132nd out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Kronos Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kronos Bio has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.69% of the float of Kronos Bio has been sold short.
Short Interest Ratio / Days to Cover
Kronos Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kronos Bio has recently decreased by 0.42%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Kronos Bio does not currently pay a dividend.
Dividend Growth
Kronos Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KRON.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for KRON on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
3 people have added Kronos Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kronos Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,736.00 in company stock.
Percentage Held by Insiders
23.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kronos Bio are expected to grow in the coming year, from ($1.74) to ($1.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kronos Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kronos Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kronos Bio has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Kronos Bio Stock (NASDAQ:KRON)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

KRON Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRON Stock News Headlines

March 31, 2024 | msn.com

5 Boutique Fitness Studios in Bangkok for an Elevated Workout Experience

March 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 21, 2024 | benzinga.com

Recap: Kronos Bio Q4 Earnings

March 21, 2024 | msn.com

Kronos Bio reports Q4 results

March 21, 2024 | investorplace.com

KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023

March 21, 2024 | globenewswire.com

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

March 19, 2024 | seekingalpha.com

KRON Kronos Bio, Inc.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 8, 2024 | bizjournals.com

Cancer drug developer Kronos Bio slashes staffing for 2nd time in 4 months

March 7, 2024 | marketwatch.com

Kronos Bio to Cut About 21% of Workforce

March 7, 2024 | globenewswire.com

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

March 5, 2024 | globenewswire.com

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

February 27, 2024 | globenewswire.com

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

February 27, 2024 | finance.yahoo.com

Kronos Bio, Inc. (KRON)

February 26, 2024 | finance.yahoo.com

KRON Mar 2024 2.500 put

February 22, 2024 | edition.cnn.com

Kronos Bio Inc

February 21, 2024 | msn.com

Single Pass’ biopsy device completes initial live clinical cases in Italy

February 21, 2024 | finance.yahoo.com

Groundbreaking Live Clinical Cases Completed with the Single Pass KRONOS Biopsy Closure Device

January 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Kronos Bio Amid Restructuring and Promising KB-0742 Clinical Data

January 25, 2024 | msn.com

Kronos Bio streamlines leadership, cuts CMO,CSO and COO roles

January 25, 2024 | finance.yahoo.com

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

December 20, 2023 | finanznachrichten.de

Kronos Bio, Inc.: Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

December 19, 2023 | benzinga.com

Kronos Bio Stock (NASDAQ:KRON), Analyst Ratings, Price Targets, Predictions

December 19, 2023 | markets.businessinsider.com

Kronos Bio Receives Buy Rating from Analyst Amid Promising Pipeline Developments

December 19, 2023 | markets.businessinsider.com

Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study

December 18, 2023 | marketwatch.com

Kronos Bio: Data From Lanraplenib Study to Treat Type of Leukemia Doesn't Support Continuing to Phase 2

See More Headlines

Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KRON
CUSIP: N/A
CIK: 1741830
Web: kronosbio.com
Phone: 650-781-5200
Fax: N/A
Employees: 62
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.25
High Stock Price Target: $6.00
Low Stock Price Target: $2.50
Potential Upside/Downside: +312.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,670,000.00
Net Margins: -1,791.87%
Pretax Margin: -1,791.87%
Return on Equity: -58.79%
Return on Assets: -45.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.24
Quick Ratio: 7.24

Sales & Book Value

Annual Sales: $6.29 million
Price / Sales: 9.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.73 per share
Price / Book: 0.38

Miscellaneous

Outstanding Shares: 60,100,000
Free Float: 46,033,000
Market Cap: $61.90 million
Optionable: Optionable
Beta: 1.82

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Norbert W. Bischofberger Ph.D. (Age 68)
President, CEO & Director
Comp: $809.7k
Mr. Joshua A. Kazam (Age 47)
Co-Founder & Director
Comp: $40k
Ms. Sandra A. Gardiner (Age 58)
Interim CFO & Principal Accounting Officer
Dr. Margaux Bennett Ph.D.
Vice President of Corporate Development & Investor Relations
Ms. Allison Frisbee J.D. (Age 41)
Senior Vice President of Corporate Operations & Legal
Dr. Charles Lin Ph.D. (Age 39)
Senior Vice President of Research & Development
Dr. Elizabeth A. Olek D.O. (Age 59)
M.P.H., Senior Vice President of Clinical Development
Mr. Wes Trotter Ph.D.
Senior Vice President of Drug Discovery & Pharmaceutical Development
Ms. Rocio Martin Hoyos
Senior Vice President of Corporate Strategy & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Kronos Bio stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KRON shares.
View KRON analyst ratings or view top-rated stocks.
What is Kronos Bio's stock price target for 2024?: 2 brokerages have issued 12 month target prices for Kronos Bio's stock. Their KRON share price targets range from $2.50 to $6.00. On average, they expect the company's share price to reach $4.25 in the next twelve months. This suggests a possible upside of 312.6% from the stock's current price.
View analysts price targets for KRON or view top-rated stocks among Wall Street analysts.
How have KRON shares performed in 2024?: Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON stock has decreased by 17.6% and is now trading at $1.03.
View the best growth stocks for 2024 here.
When is Kronos Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our KRON earnings forecast.

How were Kronos Bio's earnings last quarter?: Kronos Bio, Inc. (NASDAQ:KRON) issued its earnings results on Thursday, March, 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $2.29 million for the quarter, compared to analysts' expectations of $1.50 million. Kronos Bio had a negative trailing twelve-month return on equity of 58.79% and a negative net margin of 1,791.87%.
When did Kronos Bio IPO?: Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.
How do I buy shares of Kronos Bio?: Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRON) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial